Opendata, web and dolomites

BIOXPLOR SIGNED

BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BIOXPLOR project word cloud

Explore the words cloud of the BIOXPLOR project. It provides you a very rough idea of what is the project "BIOXPLOR" about.

25x    secondary    proteins    gained    2m    clinical    acceleration    leads    bayer    solution    abcam    rare    institutes    biotech    biosimilars    excellence    oncology    pharma    requested    antibodies    november    inflammation    trials    revenue    tested    pipeline    score    id    immunoassays    13    2021    70    biomarker    tlr    pilots    expansion    successfully    2019    programs    ai    drug    primary    space    last    discovery    multiyear    15    novartis    progress    platform    forum    uc    revenues    acquiring    submission    submissions    software    patient    inflammatory    repositioning    companies    projected    building    recombinant    environments    accelerates    eur750k    march    partnered    savings    2018    bioxplor    genomes    company    skydeck    reduces    contracts    indication    academic    merck    responder    5x    orders    cognitive    negotiating    berkeley    tests    customers    stratification    deploying    super    edemedx    shown    stage    09    seal    data    diseases    time    100k    eur500k   

Project "BIOXPLOR" data sheet

The following table provides information about the project.

Coordinator
BIOXPLOR LIMITED 

Organization address
address: 9C THE BOTTLEWORKS
city: Dublin
postcode: Dublin 4
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website https://bioxplor.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOXPLOR LIMITED IE (Dublin) coordinator 50˙000.00

Map

 Project objective

BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data. The technology has shown a 5-25x reduction in time and 70% cost savings in pilots so far. (TLR stage 6 &7 tests in 5x Biotech and Pharma companies). BioXplor has achieved the Seal of Excellence for our Phase I application in March 2019 (score 13.5) and November 2018 (score 13.09) submissions. Last year, we have been completed acceleration programs at UC Berkeley’s SkyDeck and at Merck, and since then significant progress in building the platform to TLR stage 7 and acquiring new customers and revenue. The platform has been successfully used in tests with 5x Pharma and biotech companies (Merck, Bayer, Novartis, Abcam, EdemedX), and we have 5 new leads, for our platform for Discovery applications (antibodies, recombinant proteins, biomarker discovery, immunoassays, drug target ID) and Clinical applications (indication expansion, super-responder ID for drug-repositioning, and patient stratification for Biosimilars, all in inflammation projects with Biotech and Pharma). The current submission is aimed towards bringing BioXplor’s Platform to TLR stage 8, and deploying the our fully tested solution in operational environments at Pharma, Biotech and Academic Research Institutes, for which we are already negotiating pre-orders including 3 year multiyear contracts and 5-10 year partnerships. We have since partnered UC Berkeley, gained access to clinical trials patient data from a major pharma, become a discovery forum member with the 100K Genomes Project, and been selected as a consortium partner for an EU project in the oncology space. We have built a pipeline of EUR750k, with 2019 revenues projected at EUR500k and project revenues of $2M by 2021. We have been requested to deliver the solution to manage 15-20 clinical trials (secondary use of data) for a Top 2 Pharma company

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOXPLOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOXPLOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

Skye (2018)

Redefining Drone Safety and Autonomous Operation for Indoor Commercial Applications

Read More